EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy

Chunxia Feng, Ping Li iD, Qianhui Gu, Minbin Chen, Jinhua Gu

Immunity, Inflammation and Disease · 2026-05 · 14 (5)

DOI: 10.1002/iid3.70402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 06.05.2026. Verfasst von Chunxia Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China. Hauptthemen laut MEDLINE: Neoplasms, Biomarkers, Tumor, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhou Science and Technology Plan Project, Science and Technology Project of Suzhou Municipal Health Commission, Kunshan Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

PD‐1 inhibitors are increasingly used in advanced cancers, but reliable biomarkers for predicting treatment response remain limited.

Methods

In this retrospective cohort study, we analyzed 335 patients with stage IV cancers treated with anti‐PD‐1 therapy (The First People's Hospital of Kunshan, 2019–2025). A predictive model integrating peripheral blood markers and clinical factors was developed using logistic and Cox regression.

Results

Histologic subtype, dNLR ≤ 3.18, AMC ≤ 0.48, and IL‐6 ≤ 12.35 were independent prognostic factors for OS and PFS (multivariate HRs reported). Patients with ≥ 3 favorable factors had significantly better outcomes. The model showed high accuracy for 1‐year survival prediction (AUC = 0.83) but limited performance beyond 3 years.

Conclusion

This study proposes a clinically feasible biomarker‐based tool to stratify PD‐1 inhibitor responders, though further validation in prospective cohorts is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsBiomarkers, TumorProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansFemaleRetrospective StudiesMalePrognosisMiddle AgedTreatment OutcomeAgedNeoplasm Staging

Stichwörter der Autor:innen

PD‐1 inhibitorsadvanced cancerperipheral blood markersprognostic biomarkerstreatment response prediction

Substanzen

Biomarkers, TumorProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China.
  • Department of Clinical Laboratory, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China.

ORCID-Profile: Ping Li

Förderung

  • Suzhou Science and Technology Plan Project
  • Science and Technology Project of Suzhou Municipal Health Commission
  • Kunshan Science and Technology Plan Project

Zitieren

APA

Feng, C., Li, P., Gu, Q., Chen, M., & Gu, J. (2026). Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy. Immunity, Inflammation and Disease, 14(5). https://doi.org/10.1002/iid3.70402

Vancouver

Feng C, Li P, Gu Q, Chen M, Gu J. Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy. Immunity, Inflammation and Disease. 2026;14(5). doi:10.1002/iid3.70402

BibTeX
@article{Feng2026,
  author = {Feng, Chunxia and Li, Ping and Gu, Qianhui and Chen, Minbin and Gu, Jinhua},
  title = {Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {5},
  doi = {10.1002/iid3.70402}
}
Kostenlos starten →